Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
This Phase II clinical trial is to study the effectiveness and safety of continuous hepatic arterial infusion (HAI) of Oxaliplatin and Fluorouracil in Patients with Unresectable Biliary tract carcinomas, and to explore a better first-line treatment regimen for these patients.
Biliary Tract Cancer
DRUG: Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine
Response rates, Describe the overall response rate with a 95% confidence interval., 4 months
Progress free survivial, Describe median PFS with a 95% confidence interval., 2 years|Toxicity of HAI, Toxicity as measured by NCI Common Toxicity Criteria, 1 months|Overall survival, Describe median overall survival with a 95% confidence interval and estimate the overall survival rate at 12 and 24 months with 24 months with a 95% confidence interval., 3 years
This Phase II clinical trial is to study the effectiveness and safety of continuous hepatic arterial infusion (HAI) of Oxaliplatin and Fluorouracil in Patients with Unresectable Biliary tract carcinomas, and to explore a better first-line treatment regimen for these patients.